CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (Trifluridine/Tipiracil) With Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer (FIERCE)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04104139
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:54.673156+00:00
Published At: 2026-04-15T00:00:00+00:00
Record Updated At: 2026-04-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Rectal Adenocarcinoma", "Stage IIA Rectal Cancer AJCC v8", "Stage IIB Rectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-15"
protocolSection.identificationModule.nctId: "NCT04104139"
protocolSection.identificationModule.officialTitle: "Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (Trifluridine/Tipiracil) With Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer (FIERCE)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.